Late Effects of Cancer Treatments

  • Noreen M. Aziz


With continued advances in strategies to detect cancer early and treat it effectively, along with the aging of the population, the number of individuals living years beyond a cancer diagnosis can be expected to continue to increase. Statistical trends show that, in the absence of other competing causes of death, 64% of adults diagnosed with cancer today can expect to be alive in 5 years.1, 2, 3, 4 Relative 5-year survival rates for those diagnosed as children (age less than 19 years) are even higher, with almost 79% of childhood cancer survivors estimated to be alive at 5 years and 75% at 10 years.5


Cancer Survivor Acute Lymphoblastic Leukemia Clin Oncol Late Effect Breast Cancer Survivor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    American Cancer Society. Cancer Facts and Figures, 2003. Atlanta, GA: American Cancer Society, 2004.Google Scholar
  2. 2.
    Aziz N, Rowland J. Trends and advances in cancer survivorship research: challenge and opportunity. Semin Radiat Oncol 2003;13:248–266.PubMedCrossRefGoogle Scholar
  3. 3.
    Jemal A, Clegg LX, Ward E, et al. Annual report to the nation on the status of cancer, 1875–2001, with a special feature regarding survival. Cancer (Phila) 2004;101:3–27.PubMedCrossRefGoogle Scholar
  4. 4.
    Rowland J, Mariotto A, Aziz N, et al. Cancer survivorship-United States, 1971–2001. MMWR 2004;53:526–529.Google Scholar
  5. 5.
    Ries LAG, Smith MA, Gurney JG, et al. (eds). Cancer incidence and survival among children and adolescents: United States SEER program 1975–1995. NIH Publication 99-4649. Bethesda, MD: National Cancer Institute, 1996.Google Scholar
  6. 6.
    Aziz NM. Long-term survivorship: late effects. In: Berger AM, Portenoy RK, Weissman DE (eds). Principles and Practice of Palliative Care and Supportive Oncology, 2nd ed. Philadelphia: Lippincott Williams & Wilkins, 2002:1019–1033.Google Scholar
  7. 7.
    Chu KC, Tarone RE, Kessler LG. Recent trends in U.S. breast cancer incidence, survival, and mortality rates. J Natl Cancer Inst 1996;88:1571–1579.PubMedCrossRefGoogle Scholar
  8. 8.
    McKean RC, Feigelson HS, Ross RK. Declining cancer rates in the 1990s. J Clin Oncol 2000;18:2258–2268.Google Scholar
  9. 9.
    Ries LAG, Wing PA, Miller DS. The annual report to the nation on the status of cancer, 1973–1997, with a special section on colorectal cancer. Cancer (Phila) 2000;88:2398–2424.PubMedCrossRefGoogle Scholar
  10. 10.
    Shusterman S, Meadows AT. Long term survivors of childhood leukemia. Curr Opin Hematol 2000;7:217–220.PubMedCrossRefGoogle Scholar
  11. 11.
    Demark-Wahnefried W, Peterson B, McBride C. Current health behaviors and readiness to pursue life-style changes among men and women diagnosed with early stage prostate and breast carcinomas. Cancer (Phila) 2000;88:674–684.PubMedCrossRefGoogle Scholar
  12. 12.
    Ganz PA. Late effects of cancer and its treatment. Semin Oncol Nurs 2001;17(4):241–248.PubMedCrossRefGoogle Scholar
  13. 13.
    Ganz PA. Cancer Survivors: Physiologic and Psychosocial Outcomes. Alexandria, VA: American Society of Clinical Oncology, 1998:118–123.Google Scholar
  14. 14.
    Schwartz CL. Long-term survivors of childhood cancer: the late effects of therapy. Oncologist 1999;4:45–54.PubMedGoogle Scholar
  15. 15.
    Brown ML, Fintor L. The economic burden of cancer. In: Greenwald P, Kramer BS, Weed DL (eds). Cancer Prevention and Control. New York: Dekker, 1995:69–81.Google Scholar
  16. 16.
    Sklar CA. Overview of the effects of cancer therapies: the nature, scale and breadth of the problem. Acta Paediatr (Suppl) 1999;88:1–4.Google Scholar
  17. 17.
    Mullan F. Seasons of survival: reflections of a physician with cancer. N Engl J Med 1995;313:270–273.CrossRefGoogle Scholar
  18. 18.
    Loescher LJ, Welch-McCaffrey D, Leigh SA. Surviving adult cancers. Part 1: Physiologic effects. Ann Intern Med 1989;111:411–432.PubMedGoogle Scholar
  19. 19.
    Welch-McCaffrey D, Hoffman B, Leigh SA. Surviving adult cancers. Part 2: Psychosocial implications. Ann Intern Med 1989;111:517–524.PubMedGoogle Scholar
  20. 20.
    Herold AH, Roetzheim RG. Cancer survivors. Primary Care 1992;19:779–791.PubMedGoogle Scholar
  21. 21.
    Marina N. Long-term survivors of childhood cancer. The medical consequences of cure. Pediatr Clin N Am 1997;44:1021–1041.CrossRefGoogle Scholar
  22. 22.
    Green DM. Late effects of treatment for cancer during childhood and adolescence. Curr Probl Cancer 2003;27(3):127–142.PubMedCrossRefGoogle Scholar
  23. 23.
    Mertens AC, Yasui Y, Neglia JP, et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: The Childhood Cancer Survivor Study. J Clin Oncol 2001;19:3163–3172.PubMedGoogle Scholar
  24. 24.
    Robison LL, Bhatia S. Review: Late-effects among survivors of leukaemia and lymphoma during childhood and adolescence. Br J Haematol 2003;122:345–356.PubMedCrossRefGoogle Scholar
  25. 25.
    Boulad F, Sands S, Sklar C. Late complications after bone marrow transplantation in children and adolescents. Curr Probl Pediatr 1998;28:273–304.PubMedCrossRefGoogle Scholar
  26. 26.
    Bhatia S, Landier W, Robison LL. Late effects of childhood cancer therapy. In: DeVita VT, Hellman S, Rosenberg SA (eds). Progress in Oncology. Sudbury: Jones and Bartlett, 2002:171–213.Google Scholar
  27. 27.
    Dreyer ZE, Blatt J, Bleyer A. Late effects of childhood cancer and its treatment. In: Pizzo PA, Poplack DG (eds). Principles and Practice of Pediatric Oncology, 4th ed. Philadelphia: Lippincott, Williams & Wilkins, 2002:1431–1461.Google Scholar
  28. 28.
    Hudson M. Late complications after leukemia therapy. In: Pui CG (ed). Childhood Leukemias. Cambridge: Cambridge University Press, 1991:463–481.Google Scholar
  29. 29.
    Blatt J, Copeland DR, Bleyer WA. Late effects of childhood cancer and its treatment. In: Pizzo PA, Poplack DG (eds). Principles and Practice of Pediatric Oncology, revised ed. Philadelphia: Lippincott, 1997:1091–1114.Google Scholar
  30. 30.
    Kirk JA, Raghupathy P, Stevens MM, et al. Growth failure and growth-hormone deficiency after treatment for acute lymphoblastic leukemia. Lancet 1987;1:190–193.PubMedCrossRefGoogle Scholar
  31. 31.
    Blatt J, Bercu BB, Gillin JC, et al. Reduced pulsatile growth hormone secretion in children after therapy for acute lymphoblastic leukemia. J Pediatr 1984;104:182–186.PubMedCrossRefGoogle Scholar
  32. 32.
    Silber JH, Littman PS, Meadows AT. Stature loss following skeletal irradiation for childhood cancer. J Clin Oncol 1990;8:304–312.PubMedGoogle Scholar
  33. 33.
    Leiper AD, Stanhope R, Preese MA, et al. Precocious or early puberty and growth failure in girls treated for acute lymphoblastic leukemia. Horm Res 1988;30:72–76.PubMedGoogle Scholar
  34. 34.
    Ogilvy-Stuart AL, Clayton PE, Shalet SM. Cranial irradiation and early puberty. J Clin Endocrinol Metab 1994;78:1282–1286.PubMedCrossRefGoogle Scholar
  35. 35.
    Furst CJ, Lundell M, Ahlback SO. Breast hypoplasia following irradiation of the female breast in infancy and early childhood. Acta Oncol 1989;28(4):519–523.PubMedGoogle Scholar
  36. 36.
    Meyers CA, Weitzner MA. Neurobehavioral functioning and quality of life in patients treated for cancer of the central nervous system. Curr Opin Oncol 1995;7:197–200.PubMedGoogle Scholar
  37. 37.
    Haupt R, Fears TR, Robeson LL, et al. Educational attainment in long-term survivors of childhood acute lymphoblastic leukemia. JAMA 1994;272:1427–1432.PubMedCrossRefGoogle Scholar
  38. 38.
    Stehbens JA, Kaleih TA, Noll RB, et al. CNS prophylaxis of childhood leukemia: what are the long-term neurological, neuropsychological and behavioral effects? Neuropsychol Rev 1991;2:147–176.PubMedCrossRefGoogle Scholar
  39. 39.
    Ochs J, Mulhern RK, Faircough D et al. Comparison of neuropsychologic function and clinical indicators of neurotoxicity in long-term survivors of childhood leukemia given cranial irradiation or parenteral methotrexate: a prospective study. J Clin Oncol 1991;9:145–151.PubMedGoogle Scholar
  40. 40.
    Ash P. The influence of radiation on fertility in man. Br J Radiol 1990;53:155–158.Google Scholar
  41. 41.
    Didi M, Didcock E, Davies HA, et al. High incidence of obesity in young adults after treatment of acute lymphoblastic leukemia in childhood. J Pediatr 1995;127:63–67.PubMedCrossRefGoogle Scholar
  42. 42.
    Oberfield SE, Soranno D, Nirenberg A, et al. Age at onset of puberty following high-dose central nervous system radiation therapy. Arch Pediat Adolesc Med 1996;150:589–592.Google Scholar
  43. 43.
    Sklar C, Mertens A, Walter A, et al. Final height after treatment for childhood acute lymphoblastic leukemia: comparison of no cranial irradiation with 1,800 and 2,400 centigrays of cranial irradiation. J Pediatr 1993;123:59–64.PubMedCrossRefGoogle Scholar
  44. 44.
    Greendale GA, Petersen L, Zibecchi L, Ganz PA. Factors related to sexual function in postmenopausal women with a history of breast cancer. Menopause 2001;8:111–119.PubMedCrossRefGoogle Scholar
  45. 45.
    Ganz PA, Greendale GA, Petersen L, Zibecchi L, Kahn B, Belin TR. Managing menopausal symptoms in breast cancer survivors: results of a randomized controlled trial. J Natl Cancer Inst 2000;5:1054–1064.CrossRefGoogle Scholar
  46. 46.
    Yancik R, Ganz PA, Varricchio CG, Conley B. Perspectives on comorbidity and cancer in older patients: approaches to expand the knowledge base. J Clin Oncol 2001;19:1147–1151.PubMedGoogle Scholar
  47. 47.
    Lipshultz SE, Colan SD, Gelber RD, et al. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991;324:808–814.PubMedCrossRefGoogle Scholar
  48. 48.
    Bu’Lock FA, Mott MG, Oakhill A, et al. Left ventricular diastolic function after anthracycline chemotherapy in childhood: relation with systolic function, symptoms and pathophysiology. Br Heart J 1995;73:340–350.Google Scholar
  49. 49.
    Goorin AM, Borow KM, Goldman A, et al. Congestive heart failure due to adriamycin cardiotoxicity: its natural history in children. Cancer (Phila) 1981;47:2810–2816.PubMedCrossRefGoogle Scholar
  50. 50.
    Steinherz LJ, Steinherz PG. Cardiac failure and dysrhythmias 6–19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol 1995;24:352–361.PubMedCrossRefGoogle Scholar
  51. 51.
    Adams MJ, Lipsitz SR, Colan SD, et al. Cardiovascular status in long-term survivors of Hodgkin’s disease treated with chest radiotherapy. J Clin Oncol 2004;22(15):3139–3148.PubMedCrossRefGoogle Scholar
  52. 52.
    Kremer LCM, van Dalen EC, Offringa M, Otenkamp J, Voute PA. Anthracycline-induced clinical heart failure in a cohort of 607 children: long-term follow-up study. J Clin Oncol 2001;19:191–196.PubMedGoogle Scholar
  53. 53.
    Sorensen K, Levitt G, Chessells J, Sullivan I. Anthracycline dose in childhood acute lymphoblastic leukemia: issues of early survival versus late cardiotoxicity. J Clin Oncol 1997;15:61–68.PubMedGoogle Scholar
  54. 54.
    Kremer LCM, van Dalen EC, Offringa M, Voute PA. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol 2002;13:503–512.PubMedCrossRefGoogle Scholar
  55. 55.
    Steinherz LJ, Steinherz PG, Tan CT, Heller G, Murphy ML. Cardiac toxicity 4–20 years after completing anthracycline therapy. JAMA 1991;266:1672–1677.PubMedCrossRefGoogle Scholar
  56. 56.
    Kremer LCM, van der Pal HJH, Offringa M, van Dalen EC, Voute PA. Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 2002;13:819–829.PubMedCrossRefGoogle Scholar
  57. 57.
    Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart disease after treatment of Hodgkin’s disease. JAMA 1993;270:1949–1955.PubMedCrossRefGoogle Scholar
  58. 58.
    Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin’s disease in children and adolescents. J Clin Oncol 1993;11:1199–1203.Google Scholar
  59. 59.
    Fajardo L, Stewart J, Cohn K. Morphology of radiation-induced heart disease. Arch Pathol 1968;86:512–519.PubMedGoogle Scholar
  60. 60.
    Minow RA, Benjamin RS, Gottlieb JA. Adriamycin (NSC-123127) cardiomyopathy: an overview with determination of risk factors. Cancer Chemother Rep 1975;6:195–201.Google Scholar
  61. 61.
    Prout MN, Richards MJ, Chung KJ, Joo P, Davis HL Jr. Adriamycin cardiotoxicity in children: case reports, literature review, and risk factors. Cancer (Phila) 1977;39:62–65.PubMedCrossRefGoogle Scholar
  62. 62.
    Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979;91:710–717.Google Scholar
  63. 63.
    Kushner JP, Hansen VL, Hammar SP. Cardiomyopathy after widely separated courses of adriamycin exacerbated by actinomycin-D and mithramycin. Cancer (Phila) 1975;36:1577–1584.PubMedCrossRefGoogle Scholar
  64. 64.
    Von Hoff DD, Rozencweig M, Piccart M. The cardiotoxicity of anticancer agents. Semin Oncol 1982;9:23–33.Google Scholar
  65. 65.
    Lipshultz SE, Lipsitz SR, Mone SM, et al. Female sex and drug dose as risk factors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 1995;332:1738–1743.PubMedCrossRefGoogle Scholar
  66. 66.
    Pratt CB, Ransom JL, Evans WE. Age-related adriamycin cardiotoxicity in children. Cancer Treat Rep 1978;62:1381–1385.PubMedGoogle Scholar
  67. 67.
    Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000;22:263–302.PubMedCrossRefGoogle Scholar
  68. 68.
    Legha SS, Benjamin RS, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982;96:133–139.PubMedGoogle Scholar
  69. 69.
    Lipshultz SE, Giantris AL, Lipsitz SR, et al. Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia Protocol. J Clin Oncol 2002;20:1677–1682.PubMedCrossRefGoogle Scholar
  70. 70.
    Marks RD Jr, Agarwal SK, Constable WC. Radiation induced pericarditis in Hodgkin’s disease. Acta Radiol Ther Phys Biol 1973;12:305–312.PubMedGoogle Scholar
  71. 71.
    Martin RG, Ruckdeschel JC, Chang P, Byhardt R, Bouchard RJ, Wiernik PH. Radiation-related pericarditis. Am J Cardiol 1975;35:216–220.PubMedCrossRefGoogle Scholar
  72. 72.
    Ruckdeschel JC, Chang P, Martin RG, et al. Radiation-related pericardial effusions in patients with Hodgkin’s disease. Medicine (Baltim) 1975;54:245–259.PubMedCrossRefGoogle Scholar
  73. 73.
    Perrault DJ, Levy M, Herman JD, et al. Echocardiographic abnormalities following cardiac radiation. J Clin Oncol 1985;3:546–551.PubMedGoogle Scholar
  74. 74.
    Kadota RP, Burgert EO Jr, Driscoll DJ, Evans RG, Gilchrist GS. Cardiopulmonary function in long-term survivors of childhood Hodgkin’s lymphoma: a pilot study. Mayo Clin Proc 1988;63:362–367.PubMedGoogle Scholar
  75. 75.
    Wexler LH. Ameliorating anthracycline cardiotoxicity in children with cancer: clinical trials with dexrazoxane. Semin Oncol 1998;25:86–92.PubMedGoogle Scholar
  76. 76.
    Lipshultz SE, Rifai N, Dalton VM, et al. The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med 2004;351(2):145–153.PubMedCrossRefGoogle Scholar
  77. 77.
    Gluck S. The expanding role of epirubicin in the treatment of breast cancer. Cancer Control 2002;9(suppl 2):16–27.PubMedGoogle Scholar
  78. 78.
    Baker AF, Dorr RT. Drug interactions with the taxanes: clinical implications. Cancer Treat Rev 2001;27(4):221–233.PubMedCrossRefGoogle Scholar
  79. 79.
    Sessa C, Perotti A, Salvatorelli E, et al. Phase IB and pharmacological study of the novel taxane BMS-184476 in combination with doxorubicin. Eur J Cancer 2004;40(4):563–570.PubMedCrossRefGoogle Scholar
  80. 80.
    Jones RL, Smith IE. Efficacy and safety of trastuzumab. Expert Opin Drug Saf 2004;3(4):317–327.PubMedCrossRefGoogle Scholar
  81. 81.
    Schneider JW, Chang AY, Garratt A. Trastuzumab cardiotoxicity: speculations regarding pathophysiology and targets for further study. Semin Oncol 2002;29(3 suppl 11):22–28.PubMedCrossRefGoogle Scholar
  82. 82.
    Schneider JW, Chang AY, Rocco TP. Cardiotoxicity in signal transduction therapeutics: erbB2 antibodies and the heart. Semin Oncol 2001;28:18–26.PubMedCrossRefGoogle Scholar
  83. 83.
    Meadows AT, Gordon J, Massari DJ, Littman P, Fergusson J, Moss K. Declines in IQ scores and cognitive dysfunctions in children with acute lymphocytic leukaemia treated with cranial irradiation. Lancet 1981;2:1015–1018.PubMedCrossRefGoogle Scholar
  84. 84.
    Jankovic M, Brouwers P, Valsecchi MG, et al. Association of 1800cGy cranial irradiation with intellectual function in children with acute lymphoblastic leukaemia. ISPACC. International Study Group on Psychosocial Aspects of Childhood Cancer. Lancet 1994;344:224–227.PubMedCrossRefGoogle Scholar
  85. 85.
    Hertzberg H, Huk WJ, Ueberall MA, et al. CNS late effects after ALL therapy in childhood. Part I. Neuroradiological findings in long-term survivors of childhood ALL: an evaluation of the interferences between morphology and neuropsychological performance. The German Late Effects Working Group. Medical and Pediatric Oncology, 1997;28:387–400.PubMedCrossRefGoogle Scholar
  86. 86.
    Green DM, Zevon MA, Rock KM, Chavez F. Fatigue after treatment for Hodgkin’s disease during childhood or adolescence. Proc Am Soc Clin Oncol 2002;21:396a.Google Scholar
  87. 87.
    Price R. Therapy-related central nervous system diseases in children with acute lymphocytic leukemia. In: Mastrangelo R, Poplack DG, Riccardi R (eds). Central Nervous System Leukemia: Prevention and Treatment. Boston: Martinus-Nijhoff, 1983:71–83.Google Scholar
  88. 88.
    Peylan-Ramu N, Poplack DG, Pizzo PA, Adornato BT, Di Chiro G. Abnormal CT scans of the brain in asymptomatic children with acute lymphocytic leukemia after prophylactic treatment of the central nervous system with radiation and intrathecal chemotherapy. N Engl J Med 1978;298:815–818.PubMedCrossRefGoogle Scholar
  89. 89.
    Riccardi R, Brouwers P, Di Chiro G, Poplack DG. Abnormal computed tomography brain scans in children with acute lymphoblastic leukemia: serial long-term follow-up. J Clin Oncol 1985;3:12–18.PubMedGoogle Scholar
  90. 90.
    Mulhern RK, Reddick WE, Palmer SL, et al. Neurocognitive deficits in medulloblastoma survivors and white matter loss. Ann Neurol 1999;46:834–841.PubMedCrossRefGoogle Scholar
  91. 91.
    Packer RJ, Sutton LN, Atkins TE, et al. A prospective study of cognitive function in children receiving whole-brain radiotherapy and chemotherapy: 2-year results. J Neurosurg 1989;70:707–713.PubMedGoogle Scholar
  92. 92.
    Peckham VC, Meadows AT, Bartel N, Marrero O. Educational late effects in long-term survivors of childhood acute lymphocytic leukemia. Pediatrics 1988;81:127–133.PubMedGoogle Scholar
  93. 93.
    Moore IM, Packer RJ, Karl D, Bleyer WA. Adverse effects of cancer treatment on the central nervous system. In: Schwarta CL, Hobbie WL, Constine WL, Ruccione KS (eds). Survivors of Childhood Cancer: Assessment and Management. St. Louis: Mosby, 1994:81–95.Google Scholar
  94. 94.
    Mitby PA, Robison LL, Whitton JA, et al. Utilization of special education services among long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Cancer (Phila) 2003;97:1115–1126.PubMedCrossRefGoogle Scholar
  95. 95.
    Loge JH, Abrahamsen AF, Ekeberg O, Kaasa S. Hodgkin’s disease survivors more fatigued than the general population. J Clin Oncol 1999;17:253–261.PubMedGoogle Scholar
  96. 96.
    Knobel H, Loge JH, Lund MB, Forfang K, Nome O, Kaasa S. Late medical complications and fatigue in Hodgkin’s disease survivors. J Clin Oncol 2001;19:3226–3233.PubMedGoogle Scholar
  97. 97.
    Chessells JM. Recent advances in the management of acute leukaemia. Arch Dis Child 2000;82:438–442.PubMedCrossRefGoogle Scholar
  98. 98.
    Pui CH. Acute lymphoblastic leukemia in children. Curr Opinion Oncol 2000;12:2–12.Google Scholar
  99. 99.
    van Dam FS, Schagen SB, Muller MJ, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose versus standard-dose chemotherapy. JNCI 1998;90:210–218.PubMedCrossRefGoogle Scholar
  100. 100.
    Brezden CB, Phillips KA, Abdolell M, et al. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 2000;18:2695–2701.PubMedGoogle Scholar
  101. 101.
    Ahles TA, Saykin AJ, Noll WW, et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology 2003;12(6):612–619.PubMedCrossRefGoogle Scholar
  102. 102.
    Ganz PA. Cognitive dysfunction following adjuvant treatment of breast cancer: a new dose-limiting toxic effect? JNCI 1998;90:182–183.PubMedCrossRefGoogle Scholar
  103. 103.
    Hjermstad M, Holte H, Evensen S, Fayers P, Kaasa S. Do patients who are treated with stem cell transplantation have a healthrelated quality of life comparable to the general population after 1 year? Bone Marrow Transplant 1999;24:911–918PubMedCrossRefGoogle Scholar
  104. 104.
    Walker LG, Wesnes KP, Heys SD, Walker MB, Lolley J, Eremin O. The cognitive effects of recombinant interleukin-2 therapy: a controlled clinical trial using computerised assessments. Eur J Cancer 1996;32A:2275–2283.PubMedCrossRefGoogle Scholar
  105. 105.
    Curt GA, Breitbart W, Cella D, et al. Impact of cancer related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 2000;5:353–360.PubMedCrossRefGoogle Scholar
  106. 106.
    Ahles TA, Tope DM, Furstenberg C, Hann D, Mill L. Psychologic and neuropsychologic impact of autologous bone marrow transplantation. J Clin Oncol 1996;14:1457–1462.PubMedGoogle Scholar
  107. 107.
    Ahles TA, Silberfarb PM, Maurer LH, et al. Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B. J Clin Oncol 1998;16:1954–1960.PubMedGoogle Scholar
  108. 108.
    Mulhern RK, Kepner JL, Thomas PR, Armstrong FD, Friedman HS, Kun LE. Neuropsychologic functioning of survivors of childhood medulloblastoma randomized to receive conventional or reduced-dose craniospinal irradiation: a Pediatric Oncology Group study. Clin Oncol 1998;16:1723–1728.Google Scholar
  109. 109.
    Raymond-Speden E, Tripp G, Lawrence B, Holdaway D. Intellectual, neuropsychological, and academic functioning in long-term survivors of leukemia. J Pediatr Psychol 2000;25:59–68.PubMedCrossRefGoogle Scholar
  110. 110.
    Tannock IF, Ahles TA, Ganz PA, Van Dam FS. Cognitive impairment associated with chemotherapy for cancer: report of a workshop. J Clin Oncol 2004;22(11):2233–2239.PubMedCrossRefGoogle Scholar
  111. 111.
    Shalet SM, Beardwell CG, Twomey JA, Jones PH, Pearson D. Endocrine function following the treatment of acute leukemia in childhood. J Pediatr 1977;90:920–923.PubMedCrossRefGoogle Scholar
  112. 112.
    Robison LL, Nesbit ME Jr, Sather HN, Meadows AT, Ortega JA, Hammond GD. Height of children successfully treated for acute lymphoblastic leukemia: a report from the Late Effects Study Committee of Childrens Cancer Study Group. Med Pediatr Oncol 1985;13:14–21.PubMedCrossRefGoogle Scholar
  113. 113.
    Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin’s disease. N Engl J Med 1991;325:599–605.PubMedCrossRefGoogle Scholar
  114. 114.
    Sklar C, Whitton J, Mertens A, et al. Abnormalities of the thyroid in survivors of Hodgkin’s disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab 2000;85:3227–3232.PubMedCrossRefGoogle Scholar
  115. 115.
    Glatstein E, McHardy-Young S, Brast N, Eltringham JR, Kriss JP. Alterations in serum thyrotropin (TSH) and thyroid function following radiotherapy in patients with malignant lymphoma. J Clin Endocrinol Metab 1971;32:833–841.PubMedCrossRefGoogle Scholar
  116. 116.
    Rosenthal MB, Goldfine ID. Primary and secondary hypothyroidism in nasopharyngeal carcinoma. JAMA 1976;236:1591–1593.PubMedCrossRefGoogle Scholar
  117. 117.
    Sklar CA. Growth and neuroendocrine dysfunction following therapy for childhood cancer. Pediatr Clin N Am 1997;44:489–503.CrossRefGoogle Scholar
  118. 118.
    Berry DH, Elders MJ, Crist W, et al. Growth in children with acute lymphocytic leukemia: a Pediatric Oncology Group study. Med Pediatr Oncol 1983;11:39–45.PubMedCrossRefGoogle Scholar
  119. 119.
    Papadakis V, Tan C, Heller G, Sklar C. Growth and final height after treatment for childhood Hodgkin disease. J Pediatr Hematol/Oncol 1996;18:272–276.CrossRefGoogle Scholar
  120. 120.
    Shalet SM, Price DA, Beardwell CG, Jones PH, Pearson D. Normal growth despite abnormalities of growth hormone secretion in children treated for acute leukemia. J Pediatr 1979;94:719–722.PubMedCrossRefGoogle Scholar
  121. 121.
    Didcock E, Davies HA, Didi M, Ogilvy Stuart AL, Wales JK, Shalet SM. Pubertal growth in young adult survivors of childhood leukemia. J Clin Oncol 1995;13:2503–2507.PubMedGoogle Scholar
  122. 122.
    Katz JA, Pollock BH, Jacaruso D, Morad A. Final attained height in patients successfully treated for childhood acute lymphoblastic leukemia. J Pediatr 1993;123:546–552.PubMedCrossRefGoogle Scholar
  123. 123.
    Odame I, Reilly JJ, Gibson BE, Donaldson MD. Patterns of obesity in boys and girls after treatment for acute lymphoblastic leukaemia. Arch Dis Child 1994;71:147–149.PubMedGoogle Scholar
  124. 124.
    Van Dongen-Melman JE, Hokken-Koelega AC, Hahlen K, De Groot A, Tromp CG, Egeler RM. Obesity after successful treatment of acute lymphoblastic leukemia in childhood. Pediatr Res 1995;38:86–90.PubMedCrossRefGoogle Scholar
  125. 125.
    Sklar CA, Mertens AC, Walter A, et al. Changes in body mass index and prevalence of overweight in survivors of childhood acute lymphoblastic leukemia: role of cranial irradiation. Med Pediatr Oncol 2000;35:91–95.PubMedCrossRefGoogle Scholar
  126. 126.
    Craig F, Leiper AD, Stanhope R, Brain C, Meller ST, Nussey SS. Sexually dimorphic and radiation dose dependent effect of cranial irradiation on body mass index. Arch Dis Child 1999;81:500–510.PubMedGoogle Scholar
  127. 127.
    Oeffinger KC, Mertens AC, Sklar CA, et al. Obesity in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2003; 21:1359–1365.PubMedCrossRefGoogle Scholar
  128. 128.
    Thomson AB, Critchley HOD, Wallace WHB. Fertility and progeny. Eur J Cancer 2002;38:1634–1644.PubMedCrossRefGoogle Scholar
  129. 129.
    Lamb MA. Effects of cancer on the sexuality and fertility of women. Semin Oncol Nurs 1995;11:120–127.PubMedCrossRefGoogle Scholar
  130. 130.
    Brougham MF, Kelnar CJ, Sharpe RM, Wallace WH. Male fertility following childhood cancer: current concepts and future therapies. Asian J Androl 2003;5(4):325–337.PubMedGoogle Scholar
  131. 131.
    Wallace WH, Anderson R, Baird D. Preservation of fertility in young women treated for cancer. Lancet Oncol 2004;5(5):269–270.PubMedCrossRefGoogle Scholar
  132. 132.
    Opsahl MS, Fugger EF, Sherins RJ. Preservation of reproductive function before therapy for cancer: new options involving sperm and ovary cryopreservation. Cancer J 1997;3:189–191.Google Scholar
  133. 133.
    Oktay K, Newton H, Aubard Y, Salha O, Gosden RG. Cryopreservation of immature human oocytes and ovarian tissue: an emerging technology? Fertil Steril 1998;69:1–7.PubMedCrossRefGoogle Scholar
  134. 134.
    Donnez J, Dolmans MM, Demylle D, et al. Livebirth after orthotic transplantation of cryopreserved ovarian tissue. Lancet 2004;364(9443):1405–1410.PubMedCrossRefGoogle Scholar
  135. 135.
    Wallace WH, Pritchard J. Livebirth after cryopreserved ovarian tissue autotransplantation. Lancet 2004;364(9451):2093–2094.PubMedGoogle Scholar
  136. 136.
    Bath LE, Tydeman G, Critchley HO, Anderson RA, Baird DT, Wallace WH. Spontaneous conception in a young woman who had ovarian cortical tissue cryopreserved before chemotherapy and radiotherapy for a Ewing’s sarcoma of the pelvis: case report. Hum Reprod 2004;19(11):2569–2572.PubMedCrossRefGoogle Scholar
  137. 137.
    Wallace WH, Kelsey TW. Ovarian reserve and reproductive age may be determined from measurement of ovarian volume by transvaginal sonography. Hum Reprod 2004;19(7):1612–1617.PubMedCrossRefGoogle Scholar
  138. 138.
    Chapman RM, Sutcliffe SB, Malpas JS. Cytotoxic-induced ovarian failure in Hodgkin’s disease. II. Effects on sexual function. JAMA 1979;242:1882–1884.PubMedCrossRefGoogle Scholar
  139. 139.
    Waxman JHX, Terry YA, Wrigley PFM, et al. Gonadal function in Hodgkin’s disease: long-term follow-up of chemotherapy. Br Med J 1982;285:1612–1613.Google Scholar
  140. 140.
    Byrne J, Fears TR, Gail MH, et al. Early menopause in long-term survivors of cancer during adolescence. Am J Obstet Gynecol 1992;166:788–793.PubMedGoogle Scholar
  141. 141.
    Madsen BL, Giudice L, Donaldson SS. Radiation-induced premature menopause: a misconception. Int J Radiat Oncol Biol Phys 1995;32:1461–1464.PubMedCrossRefGoogle Scholar
  142. 142.
    Li FP, Gimbreke K, Gelber RD, et al. Outcome of pregnancy in survivors of Wilms’ tumor. JAMA 1987;257:216–219.PubMedCrossRefGoogle Scholar
  143. 143.
    Constine LS, Rubin P, Woolf PD, et al. Hyperprolactinemia and hypothyroidism following cytotoxic therapy for central nervous system malignancies. J Clin Oncol 1987;5:1841–1851.PubMedGoogle Scholar
  144. 144.
    Lushbaugh CC, Casarett GW. The effects of gonadal irradiation in clinical radiation therapy: a review. Cancer (Phila) 1976;37:1111–1125.PubMedCrossRefGoogle Scholar
  145. 145.
    Stillman RJ, Schinfeld JS, Schiff I, et al. Ovarian failure in long-term survivors of childhood malignancy. Am J Obstet Gynecol 1981;139:62–66.PubMedGoogle Scholar
  146. 146.
    Wallace WHB, Thomson AB, Kelsey TW. The radiosensitivity of the human oocyte. Hum Reprod 2003;18:117–121.PubMedCrossRefGoogle Scholar
  147. 147.
    DaCunha MF, Meistrich ML, Fuller LM, et al. Recovery of spermatogenesis after treatment for Hodgkin’s disease: limiting dose of MOPP chemotherapy. J Clin Oncol 1984;2:571–577.Google Scholar
  148. 148.
    Narayan P, Lange PH, Fraley EE. Ejaculation and fertility after extended retroperitoneal lymph node dissection for testicular cancer. J Urol 1982;127:685–688.PubMedGoogle Scholar
  149. 149.
    Schlegel PN, Walsh PC. Neuroanatomical approach to radical cystoprostatectomy with preservation of sexual function. J Urol 1987;138:1402–1406.PubMedGoogle Scholar
  150. 150.
    Rowley MJ, Leach DR, Warner GA, Heller CG. Effect of graded doses of ionizing radiation on the human testis. Radiat Res 1974;59:665–678.PubMedCrossRefGoogle Scholar
  151. 151.
    Speiser B, Rubin P, Casarett G. Aspermia following lower truncal irradiation in Hodgkin’s disease. Cancer (Phila) 1973;32:692–698.PubMedCrossRefGoogle Scholar
  152. 152.
    Shamberger RC, Sherins RJ, Rosenberg SA. The effects of postoperative adjuvant chemotherapy and radiotherapy on testicular function in men undergoing treatment for soft tissue sarcoma. Cancer (Phila) 1981:47:2368–2374.PubMedCrossRefGoogle Scholar
  153. 153.
    Green DM, Brecher ML, Lindsay AN, et al. Gonadal function in pediatric patients following treatment for Hodgkin disease. Med Pediatr Oncol 1981;9:235–244.PubMedCrossRefGoogle Scholar
  154. 154.
    Sklar C. Reproductive physiology and treatment-related loss of sex hormone production. Med Pediatr Oncol 1999;33:2–8.PubMedCrossRefGoogle Scholar
  155. 155.
    Shalet SM, Horner A, Ahmed SR, Morris-Jones PH. Leydig cell damage after testicular irradiation for lymphoblastic leukaemia. Med Pediatr Oncol 1985;13:65–68.PubMedCrossRefGoogle Scholar
  156. 156.
    Leiper AD, Grant DB, Chessells JM. Gonadal function after testicular radiation for acute lymphoblastic leukaemia. Arch Dis Child 1986;61:53–56.PubMedGoogle Scholar
  157. 157.
    Sklar CA, Robison LL, Nesbit ME, et al. Effects of radiation on testicular function in long-term survivors of childhood acute lymphoblastic leukemia: a report from the Children Cancer Study Group. J Clin Oncol 1990;8:1981–1987.PubMedGoogle Scholar
  158. 158.
    Chapman RM, Sutcliffe SB, Malpas JS. Cytotoxic-induced ovarian failure in women with Hodgkin’s disease. I. Hormone function. JAMA 1979;242:1877–1881.PubMedCrossRefGoogle Scholar
  159. 159.
    Whitehead E, Shalet SM, Jones PH, Beardwell CG, Deakin DP. Gonadal function after combination chemotherapy for Hodgkin’s disease in childhood. Arch Dis Child 1982;57:287–291.PubMedGoogle Scholar
  160. 160.
    Ortin TT, Shostak CA, Donaldson SS. Gonadal status and reproductive function following treatment for Hodgkin’s disease in childhood: the Stanford experience. Int J Radiat Oncol Biol Phys 1990;19:873–880.PubMedGoogle Scholar
  161. 161.
    Mackie EJ, Radford M, Shalet SM. Gonadal function following chemotherapy for childhood Hodgkin’s disease. Med Pediatr Oncol 1996;27:74–78.PubMedCrossRefGoogle Scholar
  162. 162.
    Goodwin PJ, Ennis M, Pritchard KI, et al. Risk of menopause during the first year after breast cancer diagnosis. J Clin Oncol 1999;17:2365–2370.PubMedGoogle Scholar
  163. 163.
    Koyama H, Wada T, Nishzawa Y, et al. Cyclophosphamide induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer (Phila) 1977;39:1403–1409.PubMedCrossRefGoogle Scholar
  164. 164.
    Byrne J, Mulvihill JJ, Myers MH, et al. Effects of treatment on fertility in long-term survivors of childhood or adolescent cancer. N Engl J Med 1987;317:1315–1321.PubMedCrossRefGoogle Scholar
  165. 165.
    Critchley HOD, Wallace WHB, Shalet SM, et al. Abdominal irradiation in childhood: the potential for pregnancy. Br J Obstet Gynecol 1992;99:392–394.Google Scholar
  166. 166.
    Critchley HOD. Factors of importance for implantation and problems after treatment for childhood cancer. Med Pediatr Oncol 1999;33:9–14.PubMedCrossRefGoogle Scholar
  167. 167.
    Bath LE, Critchley HO, Chambers SE, et al. Ovarian and uterine characteristics after total body irradiation in childhood and adolescence: response to sex steroid replacement. Br J Obstet Gynaecol 1999;106:1265–1272.PubMedGoogle Scholar
  168. 168.
    Li FP, Fine W, Jaffe N, et al. Offspring of patients treated for cancer in childhood. J Natl Cancer Inst 1979;62:1193–1197.PubMedGoogle Scholar
  169. 169.
    Hawkins MM, Smith RA, Curtice LJ. Childhood cancer survivors and their offspring studied through a postal survey of general practitioners: preliminary results. J R Coll Gen Pract 1988;38:102–105.PubMedGoogle Scholar
  170. 170.
    Byrne J, Rasmussen SA, Steinhorn SC, et al. Genetic disease in offspring of long-term survivors of childhood and adolescent cancer. Am J Hum Genet 1998;62:45–52.PubMedCrossRefGoogle Scholar
  171. 171.
    Green DM, Fine WE, Li FP. Offspring of patients treated for unilateral Wilms’ tumor in childhood. Cancer (Phila) 1982;49:2285–2288.PubMedCrossRefGoogle Scholar
  172. 172.
    Byrne L, Mulvihill JJ, Connelly RR, et al. Reproductive problems and birth defects in survivors of Wilms’ tumor and their relatives. Med Pediatr Oncol 1988;16:233–240.PubMedCrossRefGoogle Scholar
  173. 173.
    Li FP, Gimbrere K, Gelber RD, et al. Outcome of pregnancy in survivors of Wilms’ tumor. JAMA 1987;257:216–219.PubMedCrossRefGoogle Scholar
  174. 174.
    Hawkins MM, Smith RA. Pregnancy outcomes in childhood cancer survivors: probable effects of abdominal irradiation. Int J Cancer 1989;43:399–402.PubMedCrossRefGoogle Scholar
  175. 175.
    Hawkins MM. Is there evidence of a therapy-related increase in germ cell mutation among childhood cancer survivors? J Natl Cancer Inst 1991;83:1643–1650.PubMedCrossRefGoogle Scholar
  176. 176.
    Green DM, Zevon MA, Lowrie G, et al. Pregnancy outcome following treatment with chemotherapy for cancer in childhood and adolescence. N Engl J Med 1991;325:141–146.PubMedCrossRefGoogle Scholar
  177. 177.
    Nygaard R, Clausen N, Siimes MA, et al. Reproduction following treatment for childhood leukemia: a population-based prospective cohort study of fertility and offspring. Med Pediatr Oncol 1991;19:459–466.PubMedCrossRefGoogle Scholar
  178. 178.
    Dodds I, Marrett LD, Tomkins DJ, et al. Case-control study of congenital anomalies in children of cancer patients. Br Med J 1993;307:164–168.Google Scholar
  179. 179.
    Kenny LB, Nicholson HS, Brasseux C, et al. Birth defects in offspring of adult survivors of childhood acute lymphoblastic leukemia. Cancer (Phila) 1996;78:169–176.CrossRefGoogle Scholar
  180. 180.
    Green DM, Fiorello A, Zevon MA, et al. Birth defects and childhood cancer in offspring of survivors of childhood cancer. Arch Pediatr Adolesc Med 1997;151:379–383.PubMedGoogle Scholar
  181. 181.
    Mulvihill JJ, Myers MH, Connelly RR, et al. Cancer in offspring of long-term survivors of childhood and adolescent cancer. Lancet 1987;2:813–817.PubMedCrossRefGoogle Scholar
  182. 182.
    Hawkins JJ, Draper GJ, Smith RA. Cancer among 1,348 offspring of survivors of childhood cancer. Int J Cancer 1989;43:975–978.PubMedCrossRefGoogle Scholar
  183. 183.
    Sanders JE, Hawley J, Levy W, et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood 1996;87:3045–3052.PubMedGoogle Scholar
  184. 184.
    Green DM, Whitton JA, Stovall M, et al. Pregnancy outcome of partners of male survivors of childhood cancer. A report from the Childhood Cancer Survivor Study. J Clin Oncol 2003;21:716–721.PubMedCrossRefGoogle Scholar
  185. 185.
    Green DM, Whitton JA, Stovall M, et al. Pregnancy outcome of female survivors of childhood cancer. A report from the Childhood Cancer Survivor Study. Am J Obstet Gynecol 2002; 187:1070–1080.PubMedCrossRefGoogle Scholar
  186. 186.
    Horning SJ, Adhikari A, Rizk N. Effect of treatment for Hodgkin’s disease on pulmonary function: results of a prospective study. J Clin Oncol 1994;12:297–305.PubMedGoogle Scholar
  187. 187.
    Samuels ML, Douglas EJ, Holoye PV, et al. Large dose bleomycin therapy and pulmonary toxicity. JAMA 1976;235:1117–1120.PubMedCrossRefGoogle Scholar
  188. 188.
    O’Driscoll BR, Hasleton PS, Taylor PM, et al. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med 1990;323:378–382.PubMedCrossRefGoogle Scholar
  189. 189.
    Vogelzang NJ. Nephrotoxicity from chemotherapy: prevention and management. Oncology 1991;5:97–112.PubMedGoogle Scholar
  190. 190.
    Dewit L, Anninga JK, Hoefnagel CA, et al. Radiation injury in the human kidney: a prospective analysis using specific scintigraphic and biochemical endpoints. Int J Radiat Oncol Biol Phys 1990;19:977–983.PubMedGoogle Scholar
  191. 191.
    Hilkens PHE, Verweij J, Vecht CJ, Stoter G, Bent MHvd. Clinical characteristics of severe peripheral neuropathy incuded by docetaxel, taxotere. Ann Oncol 1997;8:187–190.PubMedCrossRefGoogle Scholar
  192. 192.
    Tuxen MK, Hansen SW. Complications of treatment: neurotoxicity secondary to antineoplastic drugs. Cancer Treat Rev 1994; 20:191–214.PubMedCrossRefGoogle Scholar
  193. 193.
    Bhatia S, Robison LL, Meadows AT, LESG Investigators. High risk of second malignant neoplasms (SMN) continues with extended follow-up of childhood Hodgkin’s disease (HD) cohort: report from the Late Effects Study Group. Blood 2001;98:768a.Google Scholar
  194. 194.
    van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin’s disease. J Natl Cancer Inst 1995;87:1530–1537.PubMedCrossRefGoogle Scholar
  195. 195.
    Kreiker J, Kattan J. Second colon cancer following Hodgkin’s disease. A case report. J Med Libanais 1996;44:107–108.Google Scholar
  196. 196.
    Deutsch M, Wollman MR, Ramanathan R, Rubin J. Rectal cancer twenty-one years after treatment of childhood Hodgkin disease. Med Pediatr Oncol 2002;38:280–281.PubMedCrossRefGoogle Scholar
  197. 197.
    Hawkins MM, Draper GJ, Kingston JE. Incidence of second primary tumors among childhood cancer survivors. Br J Cancer 1984;56:339–347.Google Scholar
  198. 198.
    Meadows AT, Baum E, Fossati-Bellani F, et al. Second malignant neoplasms in children: an update from the Late Effects Study Group. J Clin Oncol 1985;3:532–538.PubMedGoogle Scholar
  199. 199.
    Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin’s disease. N Engl J Med 1996;334:745–751.PubMedCrossRefGoogle Scholar
  200. 200.
    Malkin D, Li FP, Strong LC, et al. Germline p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1333–1338.CrossRefGoogle Scholar
  201. 201.
    Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst 2001;93:618–629.PubMedCrossRefGoogle Scholar
  202. 202.
    Bhatia S, Sather HN, Pabustan OB, Trigg ME, Gaynon PS, Robison LL. Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood 2002;99:4257–4264.PubMedCrossRefGoogle Scholar
  203. 203.
    Neglia JP, Meadows AT, Robison LL, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med 1991;325:1330–1336.PubMedCrossRefGoogle Scholar
  204. 204.
    Relling MV, Rubnitz JE, Rivera GK, et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 1999:354:34–39.PubMedCrossRefGoogle Scholar
  205. 205.
    Hawkins MM, Wilson LM, Stovall MA, et al. Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer. Br Med J 1992;304:951–958.Google Scholar
  206. 206.
    Tucker MA. Solid second cancers following Hodgkin’s disease. Hematol-Oncol Clin N Am 1993;7:389–400.Google Scholar
  207. 207.
    Beatty O III, Hudson MM, Greenwald C, et al. Subsequent malignancies in children and adolescents after treatment for Hodgkin’s disease. J Clin Oncol 1995;13:603–609.Google Scholar
  208. 208.
    Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin’s disease. N Engl J Med 1996;334:745–751.PubMedCrossRefGoogle Scholar
  209. 209.
    Jenkin D, Greenberg M, Fitzgerald A. Second malignant tumours in childhood Hodgkin’s disease. Med Pediatr Oncol 1996;26:373–379.PubMedCrossRefGoogle Scholar
  210. 210.
    Sankila R, Garwicz S, Olsen JH, et al. Risk of subsequent malignant neoplasms among 1,641 Hodgkin’s disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology. J Clin Oncol 1996;14:1442–1446.PubMedGoogle Scholar
  211. 211.
    Wolden SL, Lamborn KR, Cleary SF, Tate DJ, Donaldson SS. Second cancers following pediatric Hodgkin’s disease. J Clin Oncol 1998;16:536–544.PubMedGoogle Scholar
  212. 212.
    Green DM, Hyland A, Barcos MP, et al. Second malignant neoplasms after treatment for Hodgkin’s disease in childhood or adolescence. J Clin Oncol 2000;18:1492–1499.PubMedGoogle Scholar
  213. 213.
    Metayer C, Lynch CF, Clarke EA, et al. Second cancers among long-term survivors of Hodgkin’s disease diagnosed in childhood and adolescence. J Clin Oncol 2000;18:2435–2443.PubMedGoogle Scholar
  214. 214.
    Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1–21.PubMedCrossRefGoogle Scholar
  215. 215.
    Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995;30:445–600.PubMedGoogle Scholar
  216. 216.
    Raunio H, Husgafvel-Pursiainen K, Anttila S, Hietanen E, Hirvonen A, Pelkonen O. Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility: a review. Gene (Amst) 1995;159:113–121.PubMedCrossRefGoogle Scholar
  217. 217.
    Smith G, Stanley LA, Sim E, Strange RC, Wolf CR. Metabolic polymorphisms and cancer susceptibility. Cancer Surv 1995; 25:27–65.PubMedGoogle Scholar
  218. 218.
    Felix CA, Walker AH, Lange BJ, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci U S A 1998;95:13176–13181.PubMedCrossRefGoogle Scholar
  219. 219.
    Naoe T, Takeyama K, Yokozawa T, et al. Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res 2000;6:4091–4095.PubMedGoogle Scholar
  220. 220.
    Blanco JG, Edick MJ, Hancock ML, et al. Genetic polymorphisms in CYP3A5, CYP3A4 and NQO1 in children who developed therapy-related myeloid malignancies. Pharmacogenetics 2002;12:605–611.PubMedCrossRefGoogle Scholar
  221. 221.
    Zim S, Collins JM, O’Neill D, et al. Inhibition of first-pass metabolism in cancer chemotherapy: interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther 1983; 34:810–817.CrossRefGoogle Scholar
  222. 222.
    Hildreth NG, Shore RE, Dvortesky PM. The risk of breast cancer after irradiation of the thymus in infancy. N Engl J Med 1989;321:1281–1284.PubMedCrossRefGoogle Scholar
  223. 223.
    Petrek JA, Heelan MC. Incidence of breast carcinoma-related lymphedema. Cancer (Phila) 1998;83(suppl 12):2776–2781.PubMedCrossRefGoogle Scholar
  224. 224.
    Erickson VS, Pearson ML, Ganz PA, Adams J, Kahn KL. Arm edema in breast cancer patients. JNCI 2004;93:96–111.CrossRefGoogle Scholar
  225. 225.
    Andrykowski MA, Curran SL, Lightner R. Off-treatment fatigue in breast cancer survivors: a controlled comparison. J Behav Med 1998;21:1–18.PubMedCrossRefGoogle Scholar
  226. 226.
    Broeckel JA, Jacobsen PB, Horton J, Balducci L, Lyman GH. Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol 1998;16:1689–1696.PubMedGoogle Scholar
  227. 227.
    Greenberg DB, Kornblith AB, Herndon JE, et al. Quality of life for adult leukemia survivors treated on clinical trials of Cancer and Leukemia Group B during the period 1971–1988. Cancer (Phila) 1997;80:1936–1944.PubMedCrossRefGoogle Scholar
  228. 228.
    Loge JH, Abrahamsen AF, Ekeberg O, Kaasa S. Hodgkin’s disease survivors more fatigued than the general population. J Clin Oncol 1999;17:253–261.PubMedGoogle Scholar
  229. 229.
    Bush NE, Haberman M, Donaldson G, Sullivan KM. Quality of life of 125 adults surviving 6–18 years after bone marrow transplant. Social Sci Med 1995;40:479–490.CrossRefGoogle Scholar
  230. 230.
    Mock V, Piper B, Escalante C, Sabbatini P. National Comprehensive Cancer Network practice guidelines for the management of cancer-related fatigue. Oncologist 2000;14(11A):151–161.Google Scholar
  231. 231.
    Ganz PA, Schag CAC, Lee JJ, et al. The CARES: a generic measure of health-related quality of life for cancer patients. Qual Life Res 1992;1:19–29.PubMedCrossRefGoogle Scholar
  232. 232.
    Demark-Wahnefried W, Aziz NM, Rowland JH, Pinto BM. Riding the Crest of the Teachable Moment: Promoting Long-Term Health after the Diagnosis of Cancer. J Clin Oncol, 2005.Google Scholar
  233. 233.
    Day RW. Future need for more cancer research. J Am Diet Assoc 1998;98:523.PubMedCrossRefGoogle Scholar
  234. 234.
    Brown BW, Brauner C, Minnotte MC. Noncancer deaths in white adult cancer patients. JNCI 1993;85:979–997.PubMedCrossRefGoogle Scholar
  235. 235.
    Meadows AT, Varricchio C, Crosson K, et al. Research issues in cancer survivorship. Cancer Epidemiol Biomarkers Prev 1998;7:1145–1151.PubMedGoogle Scholar
  236. 236.
    Travis LB. Therapy-associated solid tumors. Acta Oncol 2002; 41:323–333.PubMedCrossRefGoogle Scholar
  237. 237.
    Bergstrom A, Pisani P, Tenet V, et al. Overweight as an avoidable cause of cancer in Europe. Int J Cancer 2001;91:421–430.PubMedCrossRefGoogle Scholar
  238. 238.
    World Health Organization. IARC Handbook of Cancer Prevention, vol 6. Geneva: World Health Organization, 2002.Google Scholar
  239. 239.
    Chlebowski RT, Aiello E, McTiernan A. Weight loss in breast cancer patient management. J Clin Oncol 2002;20:1128–1143.PubMedCrossRefGoogle Scholar
  240. 240.
    Nuver J, Smit AJ, Postma A, et al. The metabolic syndrome in long-term cancer survivors, an important target for secondary measures. Cancer Treat Rev 2002;28:195–214.PubMedCrossRefGoogle Scholar
  241. 241.
    Freedland SJ, Aronson WJ, Kane CJ, et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol 2004;22:446–453.PubMedCrossRefGoogle Scholar
  242. 242.
    Argiles JM Lopez-Soriano FJ. Insulin and cancer. Int J Oncol 2001;18:683–687.PubMedGoogle Scholar
  243. 243.
    Bines J, Gradishar WJ. Primary care issues for the breast cancer survivor. Compr Ther 1997;23:605–611.PubMedGoogle Scholar
  244. 244.
    Yoshikawa T, Noguchi Y, Doi C, et al. Insulin resistance in patients with cancer: relationships with tumor site, tumor stage, body-weight loss, acute-phase response, and energy expenditure. Nutrition 2001;17:590–593.PubMedCrossRefGoogle Scholar
  245. 245.
    Balkau B, Kahn HS, Courbon D, et al. Paris Prospective Study. Hyperinsulinemia predicts fatal liver cancer but is inversely associated with fatal cancer at some other sites: the Paris Prospective Study. Diabetes Care 2001;24:843–849.PubMedCrossRefGoogle Scholar
  246. 246.
    Lamont EB, Christakis NA, Lauderdale DS. Favorable cardiac risk among elderly breast carcinoma survivors. Cancer (Phila) 2003;98:2–10.PubMedCrossRefGoogle Scholar
  247. 247.
    Hull MC, Morris CG, Pepine CJ, et al. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA 2003; 290:2831–2837.PubMedCrossRefGoogle Scholar
  248. 248.
    Buist DS, LaCroix AZ, Barlow WE, et al. Bone mineral density and endogenous hormones and risk of breast cancer in postmenopausal women (United States). Cancer Causes Control 2001;12:213–222.PubMedCrossRefGoogle Scholar
  249. 249.
    Buist DS, LaCroix AZ, Barlow WE, et al. Bone mineral density and breast cancer risk in postmenopausal women. J Clin Epidemiol 2001;54:417–422.PubMedCrossRefGoogle Scholar
  250. 250.
    Cauley JA, Lucas FL, Kuller LH, et al. Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. JAMA 1996;276:1404–1408.PubMedCrossRefGoogle Scholar
  251. 251.
    Lamont EB, Lauderdale DS. Low risk of hip fracture among elderly breast cancer survivors. Ann Epidemiol 2003;13:698–703.PubMedCrossRefGoogle Scholar
  252. 252.
    Lucas FL, Cauley JA, Stone RA, et al. Bone mineral density and risk of breast cancer: differences by family history of breast cancer. Study of Osteoporotic Fractures Research Group. Am J Epidemiol 1998;148:22–29.PubMedGoogle Scholar
  253. 253.
    Newcomb PA, Trentham-Dietz A, Egan KM, et al. Fracture history and risk of breast and endometrial cancer. Am J Epidemiol 2001;153:1071–1078.PubMedCrossRefGoogle Scholar
  254. 254.
    van der Klift M, de Laet CE, Coebergh JW, et al. Bone mineral density and the risk of breast cancer: the Rotterdam Study. Bone (NY) 2003;32:211–216.PubMedCrossRefGoogle Scholar
  255. 255.
    Zhang Y, Kiel DP, Kreger BE, et al. Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med 1997;336:611–617.PubMedCrossRefGoogle Scholar
  256. 256.
    Zmuda JM, Cauley JA, Ljung BM, et al. Study of Osteoporotic Fractures Research Group. Bone mass and breast cancer risk in older women: differences by stage at diagnosis. JNCI 2001;93:930–936.PubMedCrossRefGoogle Scholar
  257. 257.
    Schultz PN, Beck ML, Stava C, et al. Health profiles in 5836 long-term cancer survivors. Int J Cancer 2003;104:488–495.PubMedCrossRefGoogle Scholar
  258. 258.
    Twiss JJ, Waltman N, Ott CD, et al. Bone mineral density in postmenopausal breast cancer survivors. J Am Acad Nurse Pract 2001;13:276–284.PubMedCrossRefGoogle Scholar
  259. 259.
    Ramaswamy B, Shapiro CL. Osteopenia and osteoporosis in women with breast cancer. Semin Oncol 2003;30:763–775.PubMedCrossRefGoogle Scholar
  260. 260.
    Diamond TH, Higano CS, Smith MR, et al. Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer (Phila) 2004;100:892–899.PubMedCrossRefGoogle Scholar
  261. 261.
    Ko CY, Maggard M, Livingston EH: Evaluating health utility in patients with melanoma, breast cancer, colon cancer, and lung cancer: a nationwide, population-based assessment. J Surg Res 2003;114:1–5.PubMedCrossRefGoogle Scholar
  262. 262.
    Garman KS, Pieper CF, Seo P, et al. Function in elderly cancer survivors depends on comorbidities. J Gerontol A Biol Sci Med Sci 2003;58:M1119–M1124.PubMedGoogle Scholar
  263. 263.
    Hewitt M, Rowland JH, Yancik R. Cancer survivors in the U.S.: age, health and disability. J Gerontol Biol Sci Med Sci 2003; 58:82–91.Google Scholar
  264. 264.
    Ashing-Giwa K, Ganz PA, Petersen L. Quality of life of African-American and white long term breast carcinoma survivors. Cancer (Phila) 1999;85:418–426.PubMedCrossRefGoogle Scholar
  265. 265.
    Baker F, Haffer S, Denniston M. Health-related quality of life of cancer and noncancer patients in Medicare managed care. Cancer (Phila) 2003;97:674–681.PubMedCrossRefGoogle Scholar
  266. 266.
    Chirikos TN, Russell-Jacobs A, Jacobsen PB. Functional impairment and the economic consequences of female breast cancer. Womens Health 2002;36:1–20.CrossRefGoogle Scholar
  267. 267.
    Trotti A. The evolution and application of toxicity criteria. Semin Radiat Oncol 2002;12(1 suppl 1):1–3.PubMedCrossRefGoogle Scholar
  268. 268.
    Hoeller U, Tribius S, Kuhlmey A, Grader K, Fehlauer F, Alberti W. Increasing the rate of late toxicity by changing the score? A comparison of RTOG/EORTC and LENT/SOMA scores. Int J Radiat Oncol Biol Phys 2003;55(4):1013–1018.PubMedCrossRefGoogle Scholar
  269. 269.
    Garre ML, Gandus S, Cesana B, et al. Health status of long term survivors after cancer in childhood. Am J Pediatr Hematol Oncol 1994;16:143–152.PubMedGoogle Scholar
  270. 270.
    Von der Weid N, Beck D, Caflisch U, Feldges A, Wyss M, Wagner HP. Standardized assessment of late effects in long term survivors of childhood cancer in Switzerland: results of a Swiss Pediatrics Oncology Group (SPOG) study. Int J Pedatr Hematol Oncol 1996;3:483–490.Google Scholar
  271. 271.
    Brown JK, Byers T, Doyle C, et al. Nutrition and physical activity during and after cancer treatment: an American Cancer Society guide for informed choices. CA Cancer J Clin 2003;53:268–291.PubMedCrossRefGoogle Scholar
  272. 272.
    Rock CL, Demark-Wahnefried W. Nutrition and survival after the diagnosis of breast cancer: a review of the evidence. J Clin Oncol 2002;20:3302–3316.PubMedCrossRefGoogle Scholar
  273. 273.
    Kattlove H, Winn RJ. Ongoing care of patients after primary treatment for their cancer. CA Cancer J Clin 2003;53:172–196.PubMedGoogle Scholar
  274. 274.
    Robison LL. Cancer survivorship: Unique opportunities for research. Cancer Epidemiol Biomarkers Prev 2004;13:1093.PubMedGoogle Scholar
  275. 275.
    Eshelman D, Landier W, Sweeney T, Hester AL, Forte K, Darling J, Hudson MM. Facilitating care for childhood cancer survivors: integrating children’s oncology group long-term follow-up guidelines and health links in clinical practice. J Pediatr Oncol Nurs 2004;21:271–280.PubMedCrossRefGoogle Scholar
  276. 276.
    Oberfield SE, Sklar CA. Endocrine sequelae in survivors of childhood cancer. Adolesc Med 2002;13:161–169.PubMedGoogle Scholar
  277. 277.
    Green DM, Grigoriev YA, Nan B, et al. Congestive heart failure after treatment for Wilms’ tumor: a report from the National Wilms’ Tumor Study group. J Clin Oncol 2001;19:1926–1934.PubMedGoogle Scholar
  278. 278.
    Green DM, Peabody EM, Nan B, Peterson S, Kalapurakal JA, Breslow NE. Pregnancy outcome after treatment for Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol 2002;20:2506–2513.PubMedCrossRefGoogle Scholar
  279. 279.
    Michael YL, Kawachi I, Berkman LF, et al. The persistent impact of breast carcinoma on functional health status. Cancer (Phila) 2000;89:2176–2186.PubMedCrossRefGoogle Scholar
  280. 280.
    Chirikos TN, Russell-Jacobs A, Jacobsen PB. Functional impairment and the economic consequences of female breast cancer. Women Health 2002;36:1–20.PubMedCrossRefGoogle Scholar
  281. 281.
    Deimling GT, Schaefer ML, Kahana B, Bowman KF, Reardon J. Racial differences in the health of older adult long-term cancer survivors. Psychosoc Oncol (in press).Google Scholar
  282. 282.
    Chirikos TN, Russell-Jacobs A, Cantor AB. Indirect economic effects of long-term breast cancer survival. Cancer Pract 2002;10:248–255.PubMedCrossRefGoogle Scholar
  283. 283.
    Ahles TA, Saykin AJ, Furstenberg CT, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 2002; 20:485–493.PubMedCrossRefGoogle Scholar
  284. 284.
    Ahles TA, Saykin AJ, Noll WW, et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. J Clin Oncol 2002;20(2):485–493.PubMedCrossRefGoogle Scholar
  285. 285.
    Syrjala KL, Schroeder TC, Abrams JR, Atkins TZ, Sanders JE, Brown W, Heiman JR. Sexual function measurement and outcomes in cancer survivors and matched controls. J Sex Research 2000;37(3):213–225.CrossRefGoogle Scholar
  286. 286.
    Syrjala KL, Roth SL, Abrams JR, Chapko MK, Visser S, Sanders JE. Prevalence and predictors of sexual dysfunction in long-term survivors of bone marrow transplantation. J Clin Oncol 1998; 16:3148–3157.PubMedGoogle Scholar
  287. 287.
    Paskett ED, Stark N. Lymphedema: knowledge, treatment, and impact among breast cancer survivors. Breast J 2000;6(6):373–378.PubMedCrossRefGoogle Scholar
  288. 288.
    Simbre VC II, Admas MJ, Deshpande SS, Duffy SA, Miller TL, Lipshultz SE. Cardiomyopathy caused by antineoplastic therapies. Curr Treat Options Cardiovasc Med 2001;3:493–505.CrossRefGoogle Scholar
  289. 289.
    Lipshultz SE, Lipsitz SR, Sallan SE, et al. Long-term enalapril therapy for left ventricular dysfunction in doxorubicin-treated survivors of childhood cancer. J Clin Oncol 2002;20:4517–4522.PubMedCrossRefGoogle Scholar
  290. 290.
    Thompson SJ, Leigh L, Christensen R, et al. Immediate neurocognitive effects of methylphenidate on learning-impaired survivors of childhood cancer. J Clin Oncol 2001;19:1802–1808.PubMedGoogle Scholar
  291. 291.
    Longman AJ, Braden CJ, Mishel MH. Side-effects burden, psychological adjustment, and life quality in women with breast cancer: pattern of association over time. Oncol Nurs Forum 1999;26:909–915.PubMedGoogle Scholar
  292. 292.
    Badger TA, Braden CJ, Mishel MH. Depression burden, self-help interventions, and side effect experience in women receiving treatment for breast cancer. Oncol Nurs Forum 2001;28(3):567–574.PubMedGoogle Scholar
  293. 293.
    Antoni MH, Lehman JM, Kilbourn KM, et al. Cognitive-behavioral stress management intervention decreases the prevalence of depression and enhances benefit finding among women under treatment for early-stage breast cancer. Health Psychol 2001;20:20–32.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Noreen M. Aziz
    • 1
  1. 1.Office of Cancer Survivorship, Division of Cancer Control and Population ScienceNational Cancer InstituteRockvilleUSA

Personalised recommendations